185 related articles for article (PubMed ID: 18690494)
1. Clinical markers of therapeutic response to disease modifying drugs.
Pozzilli C; Prosperini L
Neurol Sci; 2008 Sep; 29 Suppl 2():S211-3. PubMed ID: 18690494
[TBL] [Abstract][Full Text] [Related]
2. What is new in the treatment of multiple sclerosis?
Weinstock-Guttman B; Jacobs LD
Drugs; 2000 Mar; 59(3):401-10. PubMed ID: 10776827
[TBL] [Abstract][Full Text] [Related]
3. A prospective, open-label treatment trial to compare the effect of IFNbeta-1a (Avonex), IFNbeta-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing--remitting multiple sclerosis: results after 18 months of therapy.
Khan OA; Tselis AC; Kamholz JA; Garbern JY; Lewis RA; Lisak RP
Mult Scler; 2001 Dec; 7(6):349-53. PubMed ID: 11795454
[TBL] [Abstract][Full Text] [Related]
4. Comparative studies of glatiramer acetate and interferon beta.
Goodin D
Int MS J; 2008 Jun; 15(2):39-41. PubMed ID: 18782497
[TBL] [Abstract][Full Text] [Related]
5. Accounting for disease modifying therapy in models of clinical progression in multiple sclerosis.
Healy BC; Engler D; Gholipour T; Weiner H; Bakshi R; Chitnis T
J Neurol Sci; 2011 Apr; 303(1-2):109-13. PubMed ID: 21251671
[TBL] [Abstract][Full Text] [Related]
6. A prospective, open-label treatment trial to compare the effect of IFN beta-1a (Avonex), IFNbeta-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing-remitting multiple sclerosis.
Khan OA; Tselis AC; Kamholz JA; Garbern JY; Lewis RA; Lisak RP
Eur J Neurol; 2001 Mar; 8(2):141-8. PubMed ID: 11284992
[TBL] [Abstract][Full Text] [Related]
7. [Immunomodulatory therapy in multiple sclerosis].
Csépány T; Bereczki D
Ideggyogy Sz; 2004 Nov; 57(11-12):401-16. PubMed ID: 15662768
[TBL] [Abstract][Full Text] [Related]
8. Current approved options for treating patients with multiple sclerosis.
Rizvi SA; Agius MA
Neurology; 2004 Dec; 63(12 Suppl 6):S8-14. PubMed ID: 15623672
[TBL] [Abstract][Full Text] [Related]
9. Interferon beta and glatiramer acetate therapy.
McGraw CA; Lublin FD
Neurotherapeutics; 2013 Jan; 10(1):2-18. PubMed ID: 23264098
[TBL] [Abstract][Full Text] [Related]
10. Pharmacogenomics of interferon beta and glatiramer acetate response: a review of the literature.
Mahurkar S; Suppiah V; O'Doherty C
Autoimmun Rev; 2014 Feb; 13(2):178-86. PubMed ID: 24189284
[TBL] [Abstract][Full Text] [Related]
11. Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.
La Mantia L; Di Pietrantonj C; Rovaris M; Rigon G; Frau S; Berardo F; Gandini A; Longobardi A; Weinstock-Guttman B; Vaona A
Cochrane Database Syst Rev; 2014 Jul; (7):CD009333. PubMed ID: 25062935
[TBL] [Abstract][Full Text] [Related]
12. Induction of apoptosis in CD4(+) T-cells is linked with optimal treatment response in patients with relapsing-remitting multiple sclerosis treated with Glatiramer acetate.
Boziki M; Lagoudaki R; Melo P; Kanidou F; Bakirtzis C; Nikolaidis I; Grigoriadou E; Afrantou T; Tatsi T; Matsi S; Grigoriadis N
J Neurol Sci; 2019 Jun; 401():43-50. PubMed ID: 31009931
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness analyses of natalizumab (Tysabri) compared with other disease-modifying therapies for people with highly active relapsing-remitting multiple sclerosis in the UK.
Gani R; Giovannoni G; Bates D; Kemball B; Hughes S; Kerrigan J
Pharmacoeconomics; 2008; 26(7):617-27. PubMed ID: 18563952
[TBL] [Abstract][Full Text] [Related]
14. Do interferon beta-1b and glatiramer acetate grow brain?
Rudick RA; Fisher E
Lancet Neurol; 2009 Dec; 8(12):1085-6; author reply 1086-7. PubMed ID: 19909906
[No Abstract] [Full Text] [Related]
15. Pharmacogenetics of multiple sclerosis: personalized therapy with immunomodulatory drugs.
Tsareva E; Kulakova O; Boyko A; Favorova O
Pharmacogenet Genomics; 2016 Mar; 26(3):103-15. PubMed ID: 26678572
[TBL] [Abstract][Full Text] [Related]
16. Disease modifying therapies modulate cardiovascular risk factors in patients with multiple sclerosis.
Sternberg Z; Leung C; Sternberg D; Yu J; Hojnacki D
Cardiovasc Ther; 2014 Apr; 32(2):33-9. PubMed ID: 24119301
[TBL] [Abstract][Full Text] [Related]
17. Assessing the long-term effectiveness of interferon-beta and glatiramer acetate in multiple sclerosis: final 10-year results from the UK multiple sclerosis risk-sharing scheme.
Palace J; Duddy M; Lawton M; Bregenzer T; Zhu F; Boggild M; Piske B; Robertson NP; Oger J; Tremlett H; Tilling K; Ben-Shlomo Y; Lilford R; Dobson C
J Neurol Neurosurg Psychiatry; 2019 Mar; 90(3):251-260. PubMed ID: 30242090
[TBL] [Abstract][Full Text] [Related]
18. Short-term suboptimal response criteria for predicting long-term non-response to first-line disease modifying therapies in multiple sclerosis: A systematic review and meta-analysis.
Río J; Ruiz-Peña JL
J Neurol Sci; 2016 Feb; 361():158-67. PubMed ID: 26810535
[TBL] [Abstract][Full Text] [Related]
19. [Additional indicators of the assessment of efficacy of disease modifying drugs (preliminary results)].
Iakushina TI; Lizhdvoĭ VIu; Vasilenko IA; Andriukhina OM; Kotov SV
Zh Nevrol Psikhiatr Im S S Korsakova; 2013; 113(2 Pt 2):61-5. PubMed ID: 23528596
[TBL] [Abstract][Full Text] [Related]
20. Concomitant therapy for multiple sclerosis.
Stuart WH; Vermersch P
Neurology; 2004 Dec; 63(11 Suppl 5):S28-34. PubMed ID: 15596733
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]